| US 7,576,212 B2 | ||
| Thieno[2,3-B] pyridines as potassium channel inhibitors | ||
| John Ford, Huntingdon (United Kingdom); Nicholas John Palmer, Cambridge (United Kingdom); John Frederick Atherall, Essex (United Kingdom); David John Madge, Cambridgeshire (United Kingdom); and Derek John, Cambridgeshire (United Kingdom) | ||
| Assigned to Xention Limited, Pampisford, Cambridge (United Kingdom) | ||
| Filed on Dec. 09, 2005, as Appl. No. 11/297,330. | ||
| Claims priority of provisional application 60/634271, filed on Dec. 09, 2004. | ||
| Prior Publication US 2006/0183768 A1, Aug. 17, 2006 | ||
| Int. Cl. C07D 513/02 (2006.01) | ||
| U.S. Cl. 546—114 | 10 Claims |
1. A compound of the formula:
 wherein
R1 is optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted cycloalkyl;
R2 is H, optionally substituted alkyl, nitro, CO2R7, CONR5R6 or halo;
R3 and R4 are H, NR5R6, NC(O)R7, halo, trifluoromethyl, optionally substituted alkyl, CONR5R6, CO2R7, cyano or optionally substituted alkoxy;
R5 and R6 may be the same or different and may be H, optionally substituted alkyl, optionally substituted aryl, optionally
substituted heteroaryl or optionally substituted cycloalkyl; or R5 and R6 may together form a saturated, unsaturated or partially
saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O
or S;
R7 is H or optionally substituted alkyl;
A is halo, or a group of formula X-L-Y;
X is O, S or NR8;
R8 is H or optionally substituted alkyl;
L is (CH2)n, where n is 1, 2, 3 or 4; and
Y is optionally substituted aryl, an optionally substituted heterocyclic group, optionally substituted alkyl, optionally substituted
alkenyl or optionally substituted cycloalkyl;
or a pharmaceutically acceptable salt thereof.
|